NEA 10 Amends Stake in GlycoMimetics

TL;DR

NEA 10 filed a 13D/A amendment for GlycoMimetics, watch for ownership changes.

AI Summary

New Enterprise Associates 10, L.P. (NEA 10) filed an amendment (No. 4) to its Schedule 13D on May 8, 2024, regarding its holdings in GlycoMimetics, Inc. The filing indicates a change in the beneficial ownership of GlycoMimetics' common stock. NEA 10, along with other NEA entities and individuals, collectively hold a significant stake in the company.

Why It Matters

This amendment signals a potential shift in the ownership structure or investment strategy of a significant institutional investor in GlycoMimetics, which could impact the company's stock performance and strategic direction.

Risk Assessment

Risk Level: medium — Amendments to Schedule 13D filings can indicate changes in activist investor intentions or significant shifts in institutional holdings, which may affect stock price volatility.

Key Players & Entities

• New Enterprise Associates 10, L.P. (company) — Filing entity
• GlycoMimetics, Inc. (company) — Subject company
• NEA 13 GP, LTD (company) — Group member
• NEA PARTNERS 10, LIMITED PARTNERSHIP (company) — Group member
• NEA PARTNERS 13, L.P. (company) — Group member
• NEW ENTERPRISE ASSOCIATES 13, L.P. (company) — Group member
• ANTHONY A. FLORENCE, JR (person) — Group member
• MOHAMAD H. MAKHZOUMI (person) — Group member
• SCOTT D. SANDELL (person) — Group member
• Stephanie Brecher (person) — Contact person for New Enterprise Associates

FAQ

Key Financial Figures

• $0.001 — 3”) relating to the common stock, $0.001 par value per share (the “Common
• $0.33 — Common Stock at prices that ranged from $0.33 to $3.17 per share. As of May 8, 2024,
• $3.17 — ock at prices that ranged from $0.33 to $3.17 per share. As of May 8, 2024, NEA 13 an

Filing Documents

• nea10-glyco_18835.htm (SC 13D/A) — 117KB
• 0001072613-24-000441.txt ( ) — 118KB

From the Filing

SC 13D/A 1 nea10-glyco_18835.htm NEW ENTERPRISE ASSOCIATES 10, L.P. / GLYCOMIMETICS -- SCHEDULE 13D/A(#4E) Schedule 13D UNITED SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D Under the Securities Exchange Act of 1934 (Amendment No. 4)* GlycoMimetics, Inc. (Name of Issuer) Common Stock, $.001 par value (Title of Class of Securities) 38000Q102 (CUSIP Number) Stephanie Brecher New Enterprise Associates 1954 Greenspring Drive, Suite 600 Timonium, MD 21093 (410) 842-4000 (Name, Address and Telephone Number of Person Authorized to Receive Notices and Communications) May 6, 2024 (Date of Event which Requires Filing of this Statement) If the filing person has previously filed a statement on Schedule 13G to report the acquisition that is the subject of this Schedule 13D, and is filing this schedule because of §§240.13d-1(e), 240.13d-1(f) or 240.13d-1(g), check the following box. Note : Schedules filed in paper format shall include a signed original and five copies of the schedule, including all exhibits. See §240.13d-7 for other parties to whom copies are to be sent. * The remainder of this cover page shall be filled out for a reporting person’s initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter disclosures provided in a prior cover page. The information required on the remainder of this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934 (“Act”) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes). CUSIP No.38000Q102 13D Page 2 of 9 Pages Item 1. Security and Issuer. This Amendment No. 4 to Schedule 13D amends and supplements the Schedule 13D originally filed on January 23, 2014 (the “Schedule 13D”), Amendment No. 1 filed on February 10, 2023 (“Amendment No. 1”), Amendment No. 2 filed on February 12, 2024 (“Amendment No. 2”), and Amendment No. 3 filed on February 29, 2024 (“Amendment No. 3”) relating to the common stock, $0.001 par value per share (the “Common Stock”) of GlycoMimetics, Inc. (the “Issuer”). having its principal executive office at 9708 Medical Center Drive, Rockville, Maryland 20850. Certain terms used but not defined in this Amendment No. 4 have the meanings assigned thereto in the Schedule 13D (and Amendment No. 1, Amendment No. 2 and Amendment No. 3 thereto). Except as specifically provided herein, this Amendment No. 4 does not modify any of the information previously reported on the Schedule 13D ((and Amendment No. 1, Amendment No. 2 and Amendment No. 3 thereto). Item 2. Identity and Background. This (a) New Enterprise Associates 10; Limited Partnership (“NEA 10”) and New Enterprise Associates 13, L.P. (“NEA 13”) (b) NEA Partners 10, Limited Partnership (“NEA Partners 10”), which is the sole general partner of NEA 10, NEA Partners 13, L.P. (“NEA Partners 13” and collectively with NEA Partners 10, the “GPLPs”), which is the sole general partner of NEA 13, NEA 13 GP, LTD (“NEA 13 LTD” and collectively with the GPLPs, the “Control Entities”) which is the sole general partner of NEA Partners 13; and (c) Forest Baskett (“Baskett”), Patrick J. Kerins (“Kerins” and collectively with Baskett, the “NEA 13-Only Directors”), Scott D. Sandell (“Sandell” and collectively with the NEA 13-Only Directors, the “Directors”), Anthony A. Florence, Jr. (“Florence”) and Mohamad H. Makhzoumi (“Makhzoumi”). The Directors are the directors of NEA 13 LTD. Sandell is also the individual general partner of NEA Partners 10 (the “Individual General Partner”). Florence and Makhzoumi are each a member of the Executive Committee of NEA Management Company, LLC (the “Executive Committee”). The persons named in this Item 2 are referred to individually herein as a “Reporting Person” and collectively as the “Reporting Persons.” The address of the principal business office of NEA 10, NEA 13, each Control Entity, Kerins, and Sandell is New Enterprise Associates, 1954 Greenspring Drive, Suite 600, Timonium, MD 21093. The address of the principal business office of Baskett and Makhzoumi is New Enterprise Associates, 2855 Sand Hill Road, Menlo Park, California 94025. The address of the principal business office of Florence is New Enterprise Associates, 104 Fifth Avenue, 19th Floor, New York, NY 10011. The principal business of NEA 10 is to invest in and assist growth-oriented businesses located principally in the United States. The principal business of NEA Pa

View Full Filing

View this SC 13D/A filing on SEC EDGAR